The Developmental Research Program is an important component of the SPORE and critical to the long-term fight against cervical cancer. It provides an avenue for soliciting new research ideas and for developing innovative high-risk, but high-impact projects to stimulate cervical cancer research in the context of the SPORE. Pilot studies provide investigators with the resources to conduct translational research consistent with the SPORE?s objectives. This program continues to encourage participation from a broad range of investigators at Johns Hopkins University (JHU), University of Colorado at Boulder (UCB), Mount Sinai Icahn School of Medicine (MSSM) and University of Alabama at Birmingham (UAB) by providing support for pilot projects with the potential to develop into more fully developed translational projects. It also encourages and facilitates the development of new research directions, methodologies, and collaborations. In addition, the JHU Sidney Kimmel Comprehensive Cancer Center also provides $75,000 annually as match funds for the Developmental Research Program. UAB will also contribute $40,000 annually to be used in the Career Development or Developmental Research program.
Specific Aims 1) Provide initiating funds for novel explorations related to cervical cancer. 2) Integrate the awardee into the SPORE community by participation in monthly meetings, group communications, and opportunities for expanded funding and for collaborations 3) Review progress and recommend avenues for continuation of successful projects

Public Health Relevance

The DRP is an important mechanism for nurturing new ideas and techniques relevant to cervical cancer to reach the level of full projects in the SPORE, and attracting new faculty members to work on cervical cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Yang, Andrew; Farmer, Emily; Lin, John et al. (2016) The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res :
Yang, Andrew; Farmer, Emily; Wu, T C et al. (2016) Perspectives for therapeutic HPV vaccine development. J Biomed Sci 23:75
Khan, Michelle J; Massad, L Stewart; Kinney, Walter et al. (2016) A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. Gynecol Oncol 141:364-70
Khan, Michelle J; Massad, L Stewart; Kinney, Walter et al. (2016) A Common Clinical Dilemma: Management of Abnormal Vaginal Cytology and Human Papillomavirus Test Results. J Low Genit Tract Dis 20:119-25
Jiang, Rosie T; Schellenbacher, Christina; Chackerian, Bryce et al. (2016) Progress and prospects for L2-based human papillomavirus vaccines. Expert Rev Vaccines 15:853-62
Wang, Yi-Shu; Chen, Jianfeng; Cui, Fengmei et al. (2016) LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors. Oncotarget :
Sun, Yun-Yan; Peng, Shiwen; Han, Liping et al. (2016) Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract. Clin Cancer Res 22:657-69
Jones, Jacqueline; Mukherjee, Angana; Karanam, Balasubramanyam et al. (2016) African Americans with pancreatic ductal adenocarcinoma exhibit gender differences in Kaiso expression. Cancer Lett 380:513-22
Randles, Leah; Anchoori, Ravi K; Roden, Richard B S et al. (2016) The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression. J Biol Chem 291:8773-83
Yang, Andrew; Jeang, Jessica; Cheng, Kevin et al. (2016) Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines 15:989-1007

Showing the most recent 10 out of 251 publications